Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NICE

- PMLiVE

Roche’s lung drug Esbriet reserved for worse cases, says NICE

Boehringer Ingelheim’s Ofev subject to same conditions

- PMLiVE

NICE backs trial of online and mobile depression programme

First digital psychological therapy briefing covers Servier and Gaia's Deprexis

Merck to pilot digital behavioural change programme

Will work with US digital therapeutics firm Blue Mesa Health in diabetes

Biogen Idec building

NICE finally starts review of Biogen’s Spinraza for SMA

Will evaluate the treatment based on its Single Technology Appraisal process

- PMLiVE

Unsure on efficacy, NICE passes J&J’s Darzalex to CDF

The bone marrow cancer therapy is now temporarily approved as a fourth-line treatment

- PMLiVE

NICE backs GSK’s €594k gene therapy for rare disease

The treatment offers 'bubble baby' patients an alternative to a stem cell transplant

National Institute for Health and Care Excellence NICE logo

NICE to look again at Pfizer’s Besponsa after appeal

The blood cancer medicine was originally turned down on cost-effectiveness grounds

Novartis day

Novartis’ Extavia evades NICE restrictions on MS drugs

But Avonex, Plegridy, Betaferon, Rebif and Copaxone are set to be turned down

Lilly boosts its forthcoming diabetes digital health offering

Strikes diabetes deal with US software and analytics firm Rimidi

Brexit talks threaten supply of medical technologies

As concern grows that the outcome could undermine the regulatory framework

- PMLiVE

NICE set to reject wider use of Eisai’s Halaven

Issues draft guidance recommending against second-line use in breast cancer

- PMLiVE

MHRA joins Instagram as part of Yellow Card drive

UK medicines regulator follows in the footsteps of NICE in using the channel

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links